Merck KGaA logo

Merck KGaA

TickerMRK.DEVenueXETRASectorHealthcarePrimary listingBeta0.81
€144.4+0.03%
FinScore58

Merck KGaA is a Germany-based company in the Healthcare sector with a market capitalisation of $70.5B. Its FinScore is 58/100; its highest-scoring layer is Momentum (88) and its lowest is Growth (30). The shares trade at 26.5x trailing earnings and are up 18% year to date.

Market cap
$70.5B
P/E (TTM)
26.5x
Dividend yield (TTM)
1.52%
ROE
8.1%

Share price performance

Loading chart…

About Merck KGaA

www.merckgroup.com

Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.

Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
HQ
Germany
Fiscal year-end
December
Trading currency
EUR
Reporting currency
EUR
Fundamentals updated
6 days ago
Market
Market cap
$70.5B
Shares outstanding
434.8M
P/E (TTM)
26.5x
Dividend yield (TTM)
1.52%
Beta (issuer)
0.79
Revenue (latest FY)
€21.1B

Revenue breakdown

Revenue split not available

FinScore

As of 2026-10-19
Overall58
Quality74
Growth30
Value47
Momentum88
Relative Strength69

Snapshot

Ownership

As of 2026-03-31
Institutional
0.0%
Insider
—
Free float
100.0%
Top-2 institutional holders
0.0%
Shares outstanding
434.8M
Sign up to see the top holders

Sign up or log in to see Analysis

Analysis for Merck KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Financials

Financials for Merck KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Estimates

Estimates for Merck KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Peers

Peers for Merck KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Valuation

Valuation for Merck KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see News

News for Merck KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.